Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc Is Being Investigated For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Edgewell Personal Care

Canoo

Rent the Runway

Constellation Brands

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Constellation Brands, Edgewell Personal Care, Rent the Runway, Medpace and Canoo.

Bet on 5 Top-Ranked Stocks With Rising P/E to Boost Your Portfolio

LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Medpace Holdings, Inc. For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings Inc Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

In the closing of the recent trading day, Medpace (MEDP) stood at $346.81, denoting a +1.39% change from the preceding trading day.

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

LOS ANGELES, CA / ACCESSWIRE / January 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholders To Join An Inquiry Into Medpace Holdings Inc For Securities Law Violations

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is.

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025

LOS ANGELES, CA / ACCESSWIRE / January 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Medpace Holdings Inc For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / December 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Here is how Medpace (MEDP) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?

Medpace (MEDP) closed the most recent trading day at $339.05, moving +0.52% from the previous trading session.

Medpace (MEDP) Rises Yet Lags Behind Market: Some Facts Worth Knowing

LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations

PACS Group, Inc.

Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?

PACS vs. MEDP: Which Stock Is the Better Value Option?

LOS ANGELES, CA / ACCESSWIRE / December 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into Medpace Holdings Inc's Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / December 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / December 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Medpace Holdings Inc For Violating Securities Laws

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / November 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Medpace Holdings Stock (MEDP)